Sign In
Get Clay Free →

Suggestions

    Kouki Harasaki

    Kouki Harasaki is a highly accomplished biochemist and business executive with a diverse range of professional experiences spanning from the pharmaceutical industry to venture capital investments. Harasaki graduated from Cornell University with a Bachelor of Arts in Biology and Asian Studies, and went on to complete his Doctor of Philosophy in Biochemistry at the University of Cambridge. Subsequently, he earned a Master of Business Administration in Healthcare and Finance from Harvard Business School.

    Harasaki has worked for several prominent organizations in the healthcare and life sciences industry, including serving as a Venture Partner for Healthcare Strategy and Investment Lead at Romulus Capital and a Partner for Bio Fund at Andreessen Horowitz. He was also previously the Chief Operating Officer at Medal, a Senior Director of Transactions, Corporate Development at Shire, and Senior Director of Oncology Search and Evaluation at Baxalta. Additionally, Harasaki held multiple leadership positions at Novartis, including Chief Executive Officer and Chief of Staff for Vaccines and Diagnostics.

    Throughout his career, Harasaki has also gained extensive experience in research, clinical development, corporate strategy, and market planning. His research work includes a Wellcome Trust Fellowship in Clinical Biochemistry at the University of Cambridge and a position as a Research Investigator in Cardiovascular and Metabolism R&D at Novartis. Additionally, he has held various clinical research assistant positions at University Hospitals and the Cleveland Clinic.

    Currently, Harasaki is a member of the Healthcare and Life Sciences investment team at M12 - Microsoft's Venture Fund. With his wide-ranging knowledge and experience in the healthcare and life sciences industry, Harasaki is a respected thought leader and an asset to any organization looking to make strategic investments or develop business growth plans.

    Highlights

    Aug 27 · science.org
    Chemokine-mediated F-actin dynamics, polarity, and migration in ...
    Nov 1 · Endpoints News
    Bioluminescence Ventures makes it official with $477M in assets for ... - Endpoints News
    Bioluminescence Ventures makes it official with $477M in assets for ... - Endpoints News
    Nov 1 · Business Wire
    Bioluminescence Ventures Emerges from Stealth with $477M AUM - Business Wire
    Bioluminescence Ventures Emerges from Stealth with $477M AUM - Business Wire

    Related Questions

    What are Kouki Harasaki's main responsibilities at M12?
    What projects has Kouki Harasaki worked on in Healthcare and Life Sciences?
    How did Kouki Harasaki get involved with Microsoft's Venture Fund?
    What is Kouki Harasaki's background before joining M12?
    What are some notable investments made by M12 under Kouki Harasaki's leadership?
    Kouki Harasaki
    Kouki Harasaki, photo 1
    Kouki Harasaki, photo 2
    Get intro to Kouki
    Add to my network